	US 11,752,163 B2
	CER-001 therapy for treating kidney disease
Jean-Louis Dasseux, Toulouse (FR); Laura Calabresi, Milan (IT); Cyrille Tupin, Castelmaurou (FR); Ronald Barbaras, Seilh (FR); and Constance Peyrottes, Le Castera (FR)
Assigned to Abionyx Pharma SA, Balma (FR)
Filed by ABIONYX PHARMA SA, Balma (FR)
Filed on Apr. 15, 2021, as Appl. No. 17/231,659.
Claims priority of provisional application 63/092,072, filed on Oct. 15, 2020.
Claims priority of provisional application 63/011,048, filed on Apr. 16, 2020.
Claims priority of application No. PCT/IB2021/00021 (WO), filed on Jan. 7, 2021.
Prior Publication US 2021/0322448 A1, Oct. 21, 2021
Int. Cl. A61K 38/00 (2006.01); C07K 14/775 (2006.01); A61P 13/12 (2006.01); A61K 31/688 (2006.01); A61K 47/24 (2006.01)

CPC A61K 31/688 (2013.01) [A61K 47/24 (2013.01); C07K 14/775 (2013.01); A61K 38/00 (2013.01)]

13 Claims

1. A method for treating a subject with glomerulopathy, kidney disease associated with lecithin cholesterol acyl transferase (LCAT) deficiency, diabetic nephropathy, chronic kidney disease (CKD), or hepatorenal syndrome (HRS), comprising:

(a) administering CER-001 to the subject according to an induction regimen comprising administering at least three doses of CER-001 to the subject separated by 1 to 3 days; and, subsequently

(b) administering CER-001 to the subject according to a consolidation regimen comprising administering at least two doses of CER-001 to the subject separated by 2 to 4 days; and, subsequently

(c) administering CER-001 to the subject according to a maintenance regimen comprising administering a dose of CER-001 to the subject once every 3 days to weekly.